Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Glenmark Pharmaceuticals Ltd. Share Price
Day's Range
Day's Range
Low
₹2,142.80
High
₹2,214.90
Price Summary
| Previous Close | ₹2,196.00 |
|---|---|
| Day's Range | ₹2,142.80 - ₹2,214.90 |
| Open | ₹2,174.90 |
| 52 Week Range | ₹1,743.20 - ₹2,474.00 |
| Volume | 5,26,651 |
| Market Cap | ₹0.06 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 11,549.22 |
|---|---|
| Market Cap (₹ in Mn) | 0.06 |
| Dividend Yield(%) | 0.11 |
| Price/Earning (TTM) | 45.48 |
| TTM EPS (₹) | 48.26 |
| P/E Ratio | 41.50 |
| Book Value(₹) | 5.89 |
| PAT Margin (%) | 3.57 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 16.16 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 32562.06 | 92264.09 |
| Expenses | N/A | N/A |
| PBT | 79.74 | 21540.18 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 43.84 | 16103.5 |
About Glenmark Pharmaceuticals Ltd.
| Founded | 1977 |
|---|---|
| Managing Director | Glenn Saldanha |
| NSE Symbol | GLENMARK |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,49,047.54 | 1,870.85 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,77,179.04 | 6,674.20 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,57,803.57 | 4,662.35 | 3,287.30 - 3,287.30 |
| Apollo Hospitals Enterprise Ltd. | 1,25,057.42 | 8,743.05 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,17,642.47 | 1,456.25 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,12,368.23 | 1,340.55 | 1,148.40 - 1,148.40 |
| Max Healthcare Institute Ltd. | 1,09,728.37 | 1,127.45 | 903.00 - 903.00 |
| Zydus Lifesciences Ltd. | 1,09,690.51 | 1,102.00 | 835.50 - 835.50 |
| Lupin Ltd. | 1,09,676.37 | 2,394.00 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,02,728.62 | 2,480.00 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Glenmark Pharmaceuticals informs about media release
Glenmark Pharmaceuticals has informed that, Glenmark Specialty S.A, a wholly owned subsidiary of the company (Glenmark) announced the advancement of its multi-country Phase 3 clinical trial for Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody drug conjugate (ADC), for patients with platinum-resistant ovarian cancer (PROC). India will serve as the first country in Glenmark’s licensed markets to initiate patient enrollment for the Phase 3 clinical trial, following the approval of Drugs Controller General of India (DCGI). Glenmark also plans to enroll patients in Australia and South Korea, subject to regulatory approvals. The company has attached media release.
The above information is a part of company’s filings submitted to BSE.
Glenmark Pharmaceuticals informs about press release
Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single‐Dose Vial. Glenmark’s Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL), of Provepharm SAS [NDA 204630]. According to IQVIA® sales data for the 12‐month period ending April 2026, the ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL) market achieved annual sales of approximately $19.0 million. The company has attached media release.
3The above information is a part of company’s filings submitted to BSE.
Glenmark Pharmaceuticals informs about press release
Glenmark Pharmaceuticals informs about investor presentation
Glenmark Pharmaceuticals informs about media release
Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch1 of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. Glenmark’s Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat®2 Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc. [NDA 022254]. According to IQVIA® sales data for the 12-month period ending April 2026, the Vimpat® Injection market3 achieved annual sales of approximately $15.2 million*. The company has attached media release in this regard.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Glenmark Pharmaceuticals Ltd. is ₹2,196.00 as of 2026-07-02.
The market capitalisation of Glenmark Pharmaceuticals Ltd. is ₹61,943.08 as of 2026-07-02.
The 1-year return of Glenmark Pharmaceuticals Ltd. is 426.00% as of 2026-07-02.
The P/E ratio of Glenmark Pharmaceuticals Ltd. is 41.50 as of 2026-07-03.
The 52-week high and low of Glenmark Pharmaceuticals Ltd. are ₹2,474.00 and ₹1,743.20, respectively, as of 2026-07-02.
People Also Ask
Glenmark offers branded generics and specialty products in dermatology, respiratory, oncology, and cardiometabolic diseases across India, emerging markets, and regulated geographies.
Glenmark partners with others via out‑licensing, co‑development, contract manufacturing, and supplies high‑volume hospital‑based therapies and complex generics globally.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
